Working to Eradicate Gynecologic Cancers

1
Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: preliminary results

Saturday, March 28, 2015: 7:55 AM
International Ballroom (Hilton Chicago)
J. Oh1, M. Barve1,2, E. A. Grosen3, B. A. Fine1, T. P. Heffernan4, C. M. Matthews1, C. A. Stringer1, E. C. Koon1, H. M. Goodman5, E. L. Fleming6, L. R. DeMars6, M. S. Bergman3, N. Senzer2,7 and J. Nemunaitis1,2,7,8
1Texas Oncology, P.A., Dallas, TX, 2Mary Crowley Cancer Research Centers, Dallas, TX, 3Cancer Care Northwest, Spokane, WA, 4North Texas Gynecologic Oncology, Dallas, TX, 5Florida Cancer Specialists, West Palm Beach, FL, 6Dartmouth Hitchcock Medical Center, Lebanon, NH, 7Gradalis, Inc., Dallas, TX, 8Medical City Dallas Hospital, Dallas, TX